Navigation Links
VEGF Trap-Eye Phase 2 Wet AMD Results Reported at ARVO Annual,Meeting

GF Trap-Eye for the treatment of wet AMD, diabetic eye diseases, and other eye diseases and disorders. Bayer HealthCare AG and Regeneron will jointly commercialize the VEGF Trap-Eye outside the United States, and Regeneron maintains exclusive rights in the United States.

In the Phase 2 wet AMD trial, data were presented from a pre-planned interim analysis of the first 78 patients who completed 12 weeks of the study. The randomized, multi-center trial involves 150 patients who were randomized to 5 groups and treated with the VEGF Trap-Eye in one eye. Two groups received either 0.5 or 2.0 milligrams (mg) of VEGF Trap-Eye administered every 4 weeks, and three groups received a single dose of 0.5, 2.0, or 4.0 mg of VEGF Trap-Eye. Patients were monitored for safety, retinal thickness, and visual acuity over 12 weeks. The VEGF Trap-Eye met its primary endpoint of a statistically significant reduction in retinal thickness after 12 weeks compared with baseline (all groups combined, decrease of 135 microns, p less than 0.0001). Mean change in visual acuity, a key secondary endpoint of the study, also demonstrated a statistically significant improvement (all groups combined, increase of 5.9 letters, p less than 0.0001). There were no drug-related serious adverse events, and treatment with the VEGF Trap-Eye was generally well-tolerated. The most common adverse events were those typically associated with intravitreal injections. Interim data for all dose groups were presented at the ARVO meeting. The Phase 2 wet AMD study is now fully enrolled and results for all patients will be presented at a future scientific meeting.

Encouraging results were also presented from a Phase 1 study of VEGF Trap-Eye in DME. In this open-label safety study, the VEGF Trap-Eye was administered as a single 4.0 mg intravitreal injection to 5 patients with longstanding diabetes and multiple prior treatments for DME. The single injection resulted in a marked decrease in mean central retina
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Positive Interim Phase 2 Data Reported for VEGF Trap-Eye in Age-Related Macular Degeneration
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: VEGF Trap Eye Phase Wet AMD Results Reported ARVO Annual Meeting
(Date:1/23/2015)... GAINESVILLE, Fla. , Jan. 23, 2015  HyGreen, Inc., ... distribution agreement and partnership with RCA Medical, a subsidiary ... Africa . Each year, hundreds of ... health care-associated infections as organisms are transmitted from patient ...
(Date:1/23/2015)... , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), ... I trial of Lixte,s lead compound, LB‑100, is being conducted, ... John S. Kovach , M.D., the founder and President ... be completed at a single site. Accrual of patients, however, ...
(Date:1/23/2015)... 2015  CytoSorbents Corporation (NASDAQ CM: CTSO), a critical ... adsorber to reduce deadly inflammation in critically-ill and ... net of transaction costs, in non-dilutive funding as ... Certificate Transfer Program sponsored by the New Jersey ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3
... HAIKOU, China, May 13, 2011 /PRNewswire-Asia-FirstCall/ -- China Pharma ... Pharma" or the "Company"), a leading fully-integrated specialty pharmaceutical ... Financial Officer, Mr. Frank Waung, has been invited to ... in New York City on May 17, 2011. Conference ...
... China, May 13, 2011 /PRNewswire-Asia/ -- Winner Medical Group ... leading manufacturer of medical dressings, medical disposables and non-woven ... today announced it will attend the Oppenheimer 5th Annual ... NY. Winner Medical will present on Tuesday, May 17th ...
Cached Medicine Technology:China Pharma Holdings, Inc. to Present at the Eighth Annual Piper Jaffray China Growth Conference in New York on May 17, 2011 2Winner Medical to Present at Oppenheimer 5th Annual China Dragon Conference 2Winner Medical to Present at Oppenheimer 5th Annual China Dragon Conference 3
(Date:1/22/2015)... Chemo Duck Program is pleased to announce the release of the ... with cancer. The Chemo Duck App, available on iTunes for use ... to help children of all ages living with cancer adjust to ... entertained, educated and at ease while waiting for clinic visits or ...
(Date:1/22/2015)... 22, 2015 The Incredible Bulk is a ... to increase lean muscle by up to 30lbs in less ... attention of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , ... a step-by-step, scientific diet formula that allows the body to ...
(Date:1/22/2015)... (PRWEB) January 23, 2015 AngelWeddingDress, the ... of 2015 maternity wedding dresses. View website ... are looking for maternity wedding dresses online for a ... gowns with high quality for them. Its maternity wedding ...
(Date:1/22/2015)... January 22, 2015 A new white ... experience and person-centeredness in the long-term care environment as ... across the continuum. The paper, “The Power of Person-Centeredness ... perspectives and practices of the patient, resident and family ...
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of ... area has treated just about every type of injury that can ... for those same twenty-plus years, the team at Doctors on ... the best possible doctor. With the combined breadth of ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2
... Efficient Operation for Gateway Healthcare , , PROVIDENCE, ... announced today that it is addressing the complex ... with the unique, next generation voice product, Cox Business ... its telecommunications services from a competitive provider to Cox ...
... marrow registry is free June 8-22; The Jeff Gordon Foundation seeds ... , MINNEAPOLIS, June 8 Every day, thousands of people ... Registry for a bone marrow match. To highlight the enormous need ... , the new name for the National Marrow Donor Program(R) Registry, ...
... ... market today, is now available to more doctors and health care professionals in Missouri through ... ... non-invasive and oral-based lead testing product in the market today, is now available to more ...
... ... sensors sizes up to 1.3 - inch format. , ... Van Nuys, CA (PRWEB) June 8, 2009 -- Schneider Optics, a ... 24mm lens. This is the third new machine vision lens Schneider has introduced in 2009. ...
... under-represented in clinical cancer research published in high-impact journals, ... University of Michigan Comprehensive Cancer Center. Taking into ... women, studies included a smaller proportion of women than ... of cancer types that were not gender specific, including ...
... Perinatology as a Medical Specialty , , WHITE PLAINS, N.Y. ... the United States and worldwide has been seen through the eyes ... evaluate an infant,s health at birth. , , Yesterday marked ... of Dimes, the organization she worked for from 1959 until her ...
Cached Medicine News:Health News:Cox Business Addresses Complex Voice Needs of Health Care Organization 2Health News:Cox Business Addresses Complex Voice Needs of Health Care Organization 3Health News:Cox Business Addresses Complex Voice Needs of Health Care Organization 4Health News:National Marrowthon Campaign Aims to Bring Nearly 50,000 to the Be The Match Registry(SM) in Two Weeks 2Health News:National Marrowthon Campaign Aims to Bring Nearly 50,000 to the Be The Match Registry(SM) in Two Weeks 3Health News:National Marrowthon Campaign Aims to Bring Nearly 50,000 to the Be The Match Registry(SM) in Two Weeks 4Health News:Parents in Missouri Can Now Test Their Children for Lead Exposure Using Saliva 2Health News:Parents in Missouri Can Now Test Their Children for Lead Exposure Using Saliva 3Health News:Parents in Missouri Can Now Test Their Children for Lead Exposure Using Saliva 4Health News:Schneider Introduces APO-Xenoplan 2.0/24mm Lens, Specially Designed for Kodak 4 MP Sensors Having Microlenses 2Health News:Schneider Introduces APO-Xenoplan 2.0/24mm Lens, Specially Designed for Kodak 4 MP Sensors Having Microlenses 3Health News:Schneider Introduces APO-Xenoplan 2.0/24mm Lens, Specially Designed for Kodak 4 MP Sensors Having Microlenses 4Health News:Women under-represented in cancer research, U-M study finds 2Health News:March of Dimes Honors 100th Anniversary of Virginia Apgar 2Health News:March of Dimes Honors 100th Anniversary of Virginia Apgar 3
... articulation maintains full inter-changeability. Modular tibial components ... fit. The Maxim Knee system is ... with expanded options to address surgeon preferences ... for use in total knee replacements both ...
Tibial distractor...
Simple, stable knee positioning triangles for lower extremity surgery. The triangles are radiolucent, autoclavable, and use latex-free, sterile, disposable pads....
... Cemex features a unique self-contained ... clinically proven in Europe for ... integrating bone cement powder and ... system, Cemex is designed to ...
Medicine Products: